Table 4.
Comparison of patients with no alteration in modified Rankin Scale (mRS) scores or alteration in mRS scores after first-line treatment.
|
No alteration in mRS scores (n = 12) |
Alteration in mRS scores (n = 28) |
P value | |
|---|---|---|---|
| Age, years, (mean ± SD) | 39.33 ± 13.50 | 34.51 ± 11.45 | 0.121 |
| Male | 4 (33.33) | 25 (89.29) | 0.011 |
| GCS score | 0.316 | ||
| 13–15 | 6 (50.00) | 20 (71.42) | |
| 5–12 | 6 (50.00) | 10 (35.71) | |
| 3–4 | 0 (0.00) | 2 (7.14) | |
| Abnormal electroencephalography | 4 (33.33) | 16 (57.14) | 0.757 |
| CSF detection | |||
| White cell count per mm3, (mean ± SD) | 34.91 ± 74.01 | 25.38 ± 46.67 | 0.612 |
| Protein concentration, mg/dL, (mean ± SD) | 0.69 ± 0.66 | 0.57 ± 0.61 | 0.590 |
| Positive antibody in CSF (%) | 12 (100.00) | 28 (100.00) | NA |
| Positive antibody in serum, (%) | 4 (33.33) | 7 (25.00) | 0.434 |
| ICU admission | 4 (33.33) | 11 (37.50) | 1.000 |
| Central hypoventilation | 6 (50.00) | 5 (17.86) | 0.048 |
| Days of immunotherapy from disease onset, mean (mean ± SD) | 22.12 ± 9.15 | 27.83 ± 17.53 | 0.451 |
| Prodrome symptoms, (%) | |||
| Fever | 5 (41.67) | 17 (60.71) | 0.498 |
| Headache | 7 (58.33) | 15 (53.57) | 0.498 |
| Dizziness | 2 (16.67) | 4 (14.29) | 0.658 |
| Clinical symptoms, (%) | |||
| Abnormal behavior | 4 (33.33) | 19 (67.86) | 0.124 |
| Movement disorder | 0 (0.00) | 2 (7.14) | 1.000 |
| Speech disorder | 2 (16.67) | 5 (17.86) | 1.000 |
| Seizures | 6 (50.00) | 12 (42.86) | 0.214 |
| Sleep disturbance | 0 (0.00) | 4 (14.29) | 0.562 |
| Memory disorder | 1 (8.33) | 8 (28.57) | 1.000 |
| Altered consciousness | 5 (41.67) | 18 (64.29) | 0.504 |
| Central hypoventilation | 6 (50.00) | 8 (28.57) | 0.045 |
| MRI findings, (%) | 0.139 | ||
| Normal | 3 (25.00) | 8 (28.57) | |
| Lesions in cerebral cortex | 5 (41.67) | 15 (53.57) | |
| Lesions in white matter | 2 (16.67) | 0 (0.00) | |
| Lesions in thalamus | 0 (0.00) | 2 (7.14) | |
| Lesions in Leptomeningea | 2 (16.67) | 3 (10.71) |